Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. develops, manufactures and sells medical technology devices used by professional healthcare providers in vascular disease, oncology and surgical settings. The company’s recurring updates center on its Med Tech portfolio, including AlphaVac and AngioVac mechanical thrombectomy products, Auryon, and the NanoKnife System for irreversible electroporation-based tumor ablation.
Company news also covers fiscal earnings, guidance changes, product adoption, reimbursement and coding topics, FDA clearances and investigational device exemptions, and expanded European indications for NanoKnife across liver, pancreas, kidney and prostate tumors. Other recurring items include pulmonary embolism research initiatives, cardiovascular scientific forums, investor conference presentations and portfolio changes following completed divestitures and discontinued product lines.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced participation in three investor conferences in March 2023. The Raymond James Institutional Investors Conference will be held on March 6 at 8:05 a.m. ET in Orlando, FL. Following that, AngioDynamics will engage in a Fireside Chat at the Oppenheimer Virtual Healthcare Conference on March 13 at 9:20 a.m. ET. Lastly, they will present at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 21 at 4:30 p.m. ET. Live webcasts will be available on their website, with replays after each event.
AngioDynamics (ANGO) reported a strong Q2 FY2023, with net sales of $85.4 million, a 9.1% increase year-over-year. Med Tech sales surged 29.7% to $24.5 million, driven by Auryon and NanoKnife products. However, the company posted a GAAP loss per share of $0.21, unchanged from the prior year. Gross margin increased to 52.8%, despite macroeconomic pressures like labor shortages. For H1 FY2023, net sales rose 7.5% to $167 million. AngioDynamics reaffirmed its FY2023 guidance for net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will present at the J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023, at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. This presentation focuses on AngioDynamics' commitment to transforming medical technology aimed at restoring vascular health and enhancing cancer treatment options. A live webcast will be available on the company's website, with a replay following the event.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its financial results for Q2 of fiscal year 2023 on January 5, 2023, before the market opens. A conference call with management will be held at 8:00 a.m. ET to discuss these results. Investors can participate by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and using the passcode 13734978. The call will also be webcast on the AngioDynamics website, with a replay available shortly after the call concludes.
AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology leader, announced that President & CEO Jim Clemmer and CFO Stephen Trowbridge will present at the Piper Sandler 34th Annual Healthcare Conference at 10:10 a.m. ET on November 30, 2022. The presentation will focus on the company's mission to enhance cancer treatment and restore healthy blood flow. Interested parties can access the live webcast through the Investors section of AngioDynamics' website, with a replay available post-event.
AngioDynamics (NASDAQ: ANGO) announced the enrollment of the first patient in the APEX-AV Study, evaluating the AlphaVac MMA F1885 System for treating acute intermediate-risk pulmonary embolism (PE). Conducted at 20 U.S. hospital sites, the study aims to assess the device's efficacy and safety. Key endpoints include RV/LV ratio reduction and the rate of major adverse events within 48 hours. This trial, in partnership with The PERT Consortium and Viz.ai, aims to improve PE care using advanced AI recruitment strategies.
AngioDynamics, a medical technology company, reported net sales of $81.5 million for the first quarter of fiscal 2023, marking a 5.9% increase from the prior year. Med Tech sales rose by 29.6% to $22.8 million, driven by solid performances from the Auryon and thrombectomy platforms. However, Med Device sales declined by 1.1% to $58.7 million. The company experienced a gross margin decrease to 51.9% and reported a net loss of $13.0 million or $0.33 per share. Fiscal year 2023 guidance is reaffirmed, expecting net sales between $342 million and $348 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will report its first quarter fiscal year 2023 financial results on October 6, 2022, before market open. Management will host a conference call at 8:00 a.m. ET the same day to discuss the results. Investors can join the conference call by dialing 1-877-407-0784 (domestic) or +1-201-689-8560 (international), using passcode 13732702. The call will be webcast on AngioDynamics' website, with a replay available shortly after the call.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that Executive Vice President and CFO, Stephen Trowbridge, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast of the presentation on AngioDynamics' website, with a replay available afterward. The company focuses on innovative medical technologies aimed at restoring blood flow, enhancing cancer treatment options, and improving patient quality of life. More information is available at www.angiodynamics.com.
AngioDynamics, Inc. (NASDAQ: ANGO) reported its fourth quarter and fiscal year 2022 results, highlighting a 13.2% increase in net sales, totaling $87.0 million. However, gross margin decreased to 53.4%, down 170 basis points year-over-year. The company posted a GAAP loss per share of $0.16 for the quarter. For the full year, net sales reached $316.2 million, with a 8.7% increase over the previous year, but also a GAAP loss per share of $0.68. Looking ahead, AngioDynamics anticipates fiscal year 2023 net sales between $342 million and $348 million.